{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:30:44Z","timestamp":1770481844623,"version":"3.49.0"},"reference-count":113,"publisher":"EDITORA SCIENTIFIC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Bras. Psiquiatr."],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1590\/1516-4446-2012-1052","type":"journal-article","created":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T15:54:57Z","timestamp":1383321297000},"page":"295-304","source":"Crossref","is-referenced-by-count":25,"title":["Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics"],"prefix":"10.47626","volume":"35","author":[{"given":"Ana Maria","family":"Volpato","sequence":"first","affiliation":[{"name":"Universidade do Extremo Sul Catarinense, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra Ioppi","family":"Zugno","sequence":"additional","affiliation":[{"name":"Universidade do Extremo Sul Catarinense, Brazil; National Science and Technology Institute for Translational Medicine; UNESC, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Quevedo","sequence":"additional","affiliation":[{"name":"Universidade do Extremo Sul Catarinense, Brazil; National Science and Technology Institute for Translational Medicine; UNESC, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27448","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1073\/pnas.0700090104","article-title":"Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden","volume":"104","author":"Meltzer HY","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neulet.2004.09.032","article-title":"Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain","volume":"372","author":"Reinke A","year":"2004","journal-title":"Neurosci Lett"},{"key":"ref3","first-page":"330","article-title":"Schizophrenia treatment. Critical review on the drugs and mechanisms of action of antipsychotics","volume":"37","author":"Tajima K","year":"2009","journal-title":"Actas Esp Psiquiatr"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality","volume":"27","author":"Bymaster FP","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim SF","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.nut.2008.06.014","article-title":"Hypothalamic neuronal histamine regulates body weight through the modulation of diurnal feeding rhythm","volume":"24","author":"Yoshimatsu H","year":"2008","journal-title":"Nutrition"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2337\/diabetes.50.2.385","article-title":"Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice","volume":"50","author":"Masaki T","year":"2001","journal-title":"Diabetes"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre JS","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth BL","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah HA","year":"2008","journal-title":"Mol Psychiatry"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.physbeh.2011.05.033","article-title":"Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism","volume":"104","author":"Teff KL","year":"2011","journal-title":"Physiol Behav"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00023210-200519001-00001","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer JW","year":"2005","journal-title":"CNS Drugs"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1176\/appi.ajp.158.10.1719","article-title":"Association of olanzapine-induced weight gain with an increase in body fat","volume":"158","author":"Eder U","year":"2001","journal-title":"Am J Psychiatry"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","article-title":"Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine","volume":"159","author":"Gothelf D","year":"2002","journal-title":"Am J Psychiatry"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.lfs.2003.08.044","article-title":"The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia","volume":"74","author":"Ryan MC","year":"2004","journal-title":"Life Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/bjp.184.1.58","article-title":"Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia","volume":"184","author":"Zhang ZJ","year":"2004","journal-title":"Br J Psychiatry"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.amepre.2008.11.020","article-title":"Obesity among those with mental disorders: a National Institute of Mental Health meeting report","volume":"36","author":"Allison DB","year":"2009","journal-title":"Am J Prev Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/070674370304800910","article-title":"Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients","volume":"48","author":"Archie S","year":"2003","journal-title":"Can J Psychiatry"},{"key":"ref19","first-page":"16","article-title":"Weight gain associated with use of psychotropic medications","volume":"60","author":"Sachs GS","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1097\/01.jcp.0000142282.62336.e9","article-title":"Atypical antipsychotics and metabolic dysregulation: evaluating the risk\/benefit equation and improving the standard of care","volume":"24","author":"Nasrallah HA","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain--a systematic review","volume":"101","author":"Taylor DM","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"ref22","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison DB","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman JA","year":"2005","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1176\/ps.50.5.704","article-title":"Weight gain among patients on clozapine","volume":"50","author":"Bai YM","year":"1999","journal-title":"Psychiatr Serv"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0924-977X(95)80001-I","article-title":"Weight gain induced by clozapine","volume":"5","author":"Hummer M","year":"1995","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2007.02.024","article-title":"Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis","volume":"93","author":"Strassnig M","year":"2007","journal-title":"Schizophr Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/00023210-200822070-00002","article-title":"Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal","volume":"22","author":"Alvarez-Jimenez M","year":"2008","journal-title":"CNS Drugs"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3949\/ccjm.74.8.597","article-title":"Atypical antipsychotics: new drugs, new challenges","volume":"74","author":"Mathews M","year":"2007","journal-title":"Cleve Clin J Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":"Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis","volume":"32","author":"Vestri HS","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2007.05.007","article-title":"Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells","volume":"56","author":"Yang LH","year":"2007","journal-title":"Pharmacol Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak MJ","year":"2002","journal-title":"Am J Psychiatry"},{"key":"ref32","first-page":"617","article-title":"Adverse effects of antipsychotic medications","volume":"81","author":"Muench J","year":"2010","journal-title":"Am Fam Physician"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients","volume":"35","author":"Nielsen J","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological mechanisms","volume":"125","author":"Reynolds GP","year":"2010","journal-title":"Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v63n0509","article-title":"A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year","volume":"63","author":"Meyer JM","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1034\/j.1600-0447.2002.2c257a.x","article-title":"Olanzapine-induced destabilization of diabetes in the absence of weight gain","volume":"105","author":"Ramankutty G","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0006-3223(01)01087-3","article-title":"Risperidone-associated new-onset diabetes","volume":"50","author":"Wirshing DA","year":"2001","journal-title":"Biol Psychiatry"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-4356(02)00588-7","article-title":"A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States","volume":"56","author":"Buse JB","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/aje\/kwj289","article-title":"Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia","volume":"164","author":"Lambert BL","year":"2006","journal-title":"Am J Epidemiol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2190\/B9RD-VMC4-CU8C-KFDD","article-title":"Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report","volume":"35","author":"Dibben CR","year":"2005","journal-title":"Int J Psychiatry Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1592\/phco.23.8.1037.32876","article-title":"Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine","volume":"23","author":"Fuller MA","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4088\/JCP.v63n1010","article-title":"Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database","volume":"63","author":"Gianfrancesco FD","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4088\/JCP.v69n0320","article-title":"Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder","volume":"69","author":"van Winkel R","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/01.jcp.0000085404.08426.3a","article-title":"Antipsychotic-induced type 2 diabetes: evidence from a large health plan database","volume":"23","author":"Gianfrancesco F","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh VL","year":"2006","journal-title":"Obesity (Silver Spring)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1590\/S1516-44462012000200009","article-title":"Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine","volume":"34","author":"Zugno AI","year":"2012","journal-title":"Rev Bras Psiquiatr"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie AJ","year":"2002","journal-title":"J Psychopharmacol"},{"key":"ref48","first-page":"121","article-title":"An animal model of antipsychotic-induced weight gain","volume":"152","author":"Arjona AA","year":"2004","journal-title":"Behav Brain Res"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0091-3057(01)00630-X","article-title":"Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol","volume":"71","author":"Lee MD","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-002-1368-8","article-title":"Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat","volume":"167","author":"Hartfield AW","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-009-1593-5","article-title":"Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats","volume":"206","author":"Victoriano M","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.lfs.2007.08.009","article-title":"Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats","volume":"81","author":"Choi S","year":"2007","journal-title":"Life Sci"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000100981","article-title":"Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation","volume":"85","author":"Tulipano G","year":"2007","journal-title":"Neuroendocrinology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00125-008-1152-3","article-title":"Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat","volume":"51","author":"Smith GC","year":"2008","journal-title":"Diabetologia"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","article-title":"Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance","volume":"957","author":"Baptista T","year":"2002","journal-title":"Brain Res"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1046\/j.1440-1681.2002.t01-1-03755.x","article-title":"Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats","volume":"29","author":"Ota M","year":"2002","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.3.10.1381","article-title":"Antipsychotics: impact on prolactin levels","volume":"3","author":"Goodnick PJ","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00213-005-0230-1","article-title":"Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data","volume":"184","author":"Rourke C","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00213-005-0131-3","article-title":"Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats","volume":"182","author":"Fell MJ","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbr.2004.12.015","article-title":"Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats","volume":"160","author":"Fell MJ","year":"2005","journal-title":"Behav Brain Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/schbul\/sbn104","article-title":"Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation","volume":"36","author":"Savoy YE","year":"2010","journal-title":"Schizophr Bull"},{"key":"ref62","first-page":"e55","article-title":"Chronic administration of olanzapine affects Behavioral Satiety Sequence and feeding behavior in female mice","volume":"13","author":"Coccurello R","year":"2008","journal-title":"Eat Weight Disord"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1677\/joe.0.160R007","article-title":"The effect of the orexins on food intake: comparison with neuropeptide Y, melanin-concentrating hormone and galanin","volume":"160","author":"Edwards CM","year":"1999","journal-title":"J Endocrinol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/0196-9781(84)90165-7","article-title":"Neuropeptide Y: a potent inducer of consummatory behavior in rats","volume":"5","author":"Levine AS","year":"1984","journal-title":"Peptides"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/380243a0","article-title":"A role for melanin-concentrating hormone in the central regulation of feeding behaviour","volume":"380","author":"Qu D","year":"1996","journal-title":"Nature"},{"key":"ref66","first-page":"E627","article-title":"Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus","volume":"274","author":"Ludwig DS","year":"1998","journal-title":"Am J Physiol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00213-008-1415-1","article-title":"Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine","volume":"203","author":"Davoodi N","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0269881106061199","article-title":"Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus","volume":"20","author":"Kirk SL","year":"2006","journal-title":"J Psychopharmacol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbr.2009.09.032","article-title":"Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance","volume":"207","author":"Guesdon B","year":"2010","journal-title":"Behav Brain Res"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biopsych.2007.12.011","article-title":"Dysregulation of the mesolimbic dopamine system and reward in MCH-\/- mice","volume":"64","author":"Pissios P","year":"2008","journal-title":"Biol Psychiatry"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"6772","DOI":"10.1073\/pnas.0811331106","article-title":"The melanin-concentrating hormone system modulates cocaine reward","volume":"106","author":"Chung S","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-8993(90)90373-J","article-title":"Hypothalamic neuronal histamine modulates ad libitum feeding by rats","volume":"537","author":"Sakata T","year":"1990","journal-title":"Brain Res"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1152\/physrev.00043.2007","article-title":"Histamine in the nervous system","volume":"88","author":"Haas HL","year":"2008","journal-title":"Physiol Rev"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/0006-8993(90)91240-H","article-title":"Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates","volume":"526","author":"Martinez-Mir MI","year":"1990","journal-title":"Brain Res"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1124\/mol.59.3.427","article-title":"Discovery of a novel member of the histamine receptor family","volume":"59","author":"Nguyen T","year":"2001","journal-title":"Mol Pharmacol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-8993(98)00186-3","article-title":"Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats","volume":"793","author":"Lecklin A","year":"1998","journal-title":"Brain Res"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/diabetes.53.9.2250","article-title":"Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity","volume":"53","author":"Masaki T","year":"2004","journal-title":"Diabetes"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze WK","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson E","year":"2000","journal-title":"Life Sci"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han M","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.pneurobio.2010.07.002","article-title":"Involvement of the brain histaminergic system in addiction and addiction-related behaviors: a comprehensive review with emphasis on the potential therapeutic use of histaminergic compounds in drug dependence","volume":"92","author":"Brabant C","year":"2010","journal-title":"Prog Neurobiol"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2004.12.003","article-title":"AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism","volume":"1","author":"Kahn BB","year":"2005","journal-title":"Cell Metab"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/153537020222700309","article-title":"Hypothalamic histamine neurons activate lipolysis in rat adipose tissue","volume":"227","author":"Tsuda K","year":"2002","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1523\/JNEUROSCI.22-15-06742.2002","article-title":"Differential activation of orexin neurons by antipsychotic drugs associated with weight gain","volume":"22","author":"Fadel J","year":"2002","journal-title":"J Neurosci"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/JCP.0b013e3181bfe13e","article-title":"30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice","volume":"29","author":"Coccurello R","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"ref86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/oby.2008.468","article-title":"The role of thermogenesis in antipsychotic drug-induced weight gain","volume":"17","author":"Stefanidis A","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004850-200503000-00007","article-title":"The effect of betahistine, a histamine H1 receptor agonist\/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients","volume":"20","author":"Poyurovsky M","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"228S","DOI":"10.1093\/ajcn\/55.1.228s","article-title":"Adrenergic receptor function in fat cells","volume":"55","author":"Arner P","year":"1992","journal-title":"Am J Clin Nutr"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1172\/JCI110055","article-title":"Pharmacological characterizations of adrenergic receptors in human adipocytes","volume":"67","author":"Burns TW","year":"1981","journal-title":"J Clin Invest"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0898-6568(95)02035-7","article-title":"Adrenoceptor heterogeneity in human white adipocytes differentiated in culture as assessed by cytosolic free calcium measurements","volume":"8","author":"Seydoux J","year":"1996","journal-title":"Cell Signal"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/jpet.301.1.229","article-title":"In vivo alpha(1)-adrenergic lipolytic activity in subcutaneous adipose tissue of obese subjects","volume":"301","author":"Flechtner-Mors M","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.160.2.297","article-title":"Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study","volume":"160","author":"Poyurovsky M","year":"2003","journal-title":"Am J Psychiatry"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata A","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4088\/JCP.v69n0909","article-title":"Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study","volume":"69","author":"Ujike H","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"ref95","first-page":"45","article-title":"Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle","volume":"62","author":"Basile VS","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0165-6147(94)90118-X","article-title":"The human beta 3-adrenoceptor: the search for a physiological function","volume":"15","author":"Emorine L","year":"1994","journal-title":"Trends Pharmacol Sci"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1002\/j.1460-2075.1991.tb04940.x","article-title":"Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes","volume":"10","author":"Nahmias C","year":"1991","journal-title":"EMBO J"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1172\/JCI116191","article-title":"Tissue distribution of beta 3-adrenergic receptor mRNA in man","volume":"91","author":"Krief S","year":"1993","journal-title":"J Clin Invest"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s001250051322","article-title":"Autonomic regulation of islet hormone secretion--implications for health and disease","volume":"43","author":"Ahren B","year":"2000","journal-title":"Diabetologia"},{"key":"ref100","first-page":"565","article-title":"Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function","volume":"22","author":"Gilon P","year":"2001","journal-title":"Endocr Rev"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1385\/ENDO:8:3:213","article-title":"Neurotransmitters and their receptors in the islets of Langerhans of the pancreas: what messages do acetylcholine, glutamate, and GABA transmit?","volume":"8","author":"Satin LS","year":"1998","journal-title":"Endocrine"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(90)90109-J","article-title":"Muscarinic receptor subtypes in rat pancreatic islets: binding and functional studies","volume":"178","author":"Verspohl EJ","year":"1990","journal-title":"Eur J Pharmacol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF02784941","article-title":"Neural regulation of the endocrine pancreas","volume":"18","author":"Brunicardi FC","year":"1995","journal-title":"Int J Pancreatol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1615\/CritRevNeurobiol.v10.i1.40","article-title":"Molecular biology of muscarinic acetylcholine receptors","volume":"10","author":"Wess J","year":"1996","journal-title":"Crit Rev Neurobiol"},{"key":"ref105","first-page":"E336","article-title":"Oxotremorine-m potentiation of glucose-induced insulin release from rat islets involves M3 muscarinic receptors","volume":"268","author":"Boschero AC","year":"1995","journal-title":"Am J Physiol"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2337\/diab.46.9.1419","article-title":"Identification of muscarinic receptor subtypes in RINm5F cells by means of polymerase chain reaction, subcloning, and DNA sequencing","volume":"46","author":"Tang SH","year":"1997","journal-title":"Diabetes"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2337\/diabetes.49.3.392","article-title":"Quantitative and functional characterization of muscarinic receptor subtypes in insulin-secreting cell lines and rat pancreatic islets","volume":"49","author":"Iismaa TP","year":"2000","journal-title":"Diabetes"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/diabetes.53.7.1714","article-title":"Muscarinic stimulation of pancreatic insulin and glucagon release is abolished in m3 muscarinic acetylcholine receptor-deficient mice","volume":"53","author":"Duttaroy A","year":"2004","journal-title":"Diabetes"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cmet.2006.04.009","article-title":"A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo","volume":"3","author":"Gautam D","year":"2006","journal-title":"Cell Metab"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"E475","DOI":"10.1152\/ajpendo.00072.2010","article-title":"Palmitic acid acutely inhibits acetylcholine- but not GLP-1-stimulated insulin secretion in mouse pancreatic islets","volume":"299","author":"Doliba NM","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","article-title":"Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia","volume":"54","author":"Johnson DE","year":"2005","journal-title":"Diabetes"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00213-006-0368-5","article-title":"Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects","volume":"186","author":"Coccurello R","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance","volume":"66","author":"Weiden PJ","year":"2004","journal-title":"Schizophr Res"}],"container-title":["Revista Brasileira de Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rbp\/v35n3\/1516-4446-rbp-2013-35-3-295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T16:12:58Z","timestamp":1654531978000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-44462013000300295&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1516-44462013000300295"],"URL":"https:\/\/doi.org\/10.1590\/1516-4446-2012-1052","relation":{},"ISSN":["1516-4446"],"issn-type":[{"value":"1516-4446","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}